Q-omics provides the consensus-scored MSX2P1 profile across patient tissues and cancer cell-line models. MSX2P1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, MSX2P1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, MSX2P1 RNA expression shows 8,429 significant gene co-expression associations, with the highest sampling consensus in STAD. Together, these results highlight PAAD, KIRC, and STAD as cancer lineages where MSX2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MSX2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MSX2P1 survival associations across molecular data types. MSX2P1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MSX2P1 RNA expression–survival associations across cancer types. High MSX2P1 expression shows unfavorable associations in READ, but favorable associations in PAAD, LGG, KIRC, HNSC and COAD. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for MSX2P1 RNA expression.
This table summarizes MSX2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MSX2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MSX2P1 shows lower tumor expression in KIRC, KIRP, KICH, COAD, LUSC and READ. The KIRC box plot shows higher MSX2P1 RNA expression in normal versus tumor tissue (log2 FC = −0.381, t-test p < 0.001).
This table shows molecular features associated with MSX2P1 in patient tissues and cancer cell lines. In patient samples, MSX2P1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MSX2P1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS.
